Your browser doesn't support javascript.
loading
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV­201): a multicentre, single-arm, phase 2 trial.
Yu, Evan Y; Petrylak, Daniel P; O'Donnell, Peter H; Lee, Jae-Lyun; van der Heijden, Michiel S; Loriot, Yohann; Stein, Mark N; Necchi, Andrea; Kojima, Takahiro; Harrison, Michael R; Hoon Park, Se; Quinn, David I; Heath, Elisabeth I; Rosenberg, Jonathan E; Steinberg, Joyce; Liang, Shang-Ying; Trowbridge, Janet; Campbell, Mary; McGregor, Bradley; Balar, Arjun V.
Afiliación
  • Yu EY; Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: evanyu@uw.edu.
  • Petrylak DP; Medical Oncology, Yale Cancer Center, Medical Oncology, New Haven, CT, USA.
  • O'Donnell PH; Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, USA.
  • Lee JL; Department of Oncology, Asan Medical Center, Songpa-gu, Seoul, South Korea; University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea.
  • van der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Loriot Y; Département de Médecine Oncologique, INSERM 981, Institut de Cancérologie Gustave Roussy, Université Paris-Saclay, Paris, France.
  • Stein MN; Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
  • Necchi A; Vita-Salute San Raffaele University, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.
  • Kojima T; University of Tsukuba, Tsukuba, Japan.
  • Harrison MR; Duke Cancer Institute Center for Prostate and Urologic Cancers, Department of Medicine, Durham, NC, USA.
  • Hoon Park S; Department of Hematology-Oncology, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea.
  • Quinn DI; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
  • Heath EI; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
  • Rosenberg JE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Steinberg J; Astellas Pharma, Northbrook, IL, USA.
  • Liang SY; Seagen, Bothell, WA, USA.
  • Trowbridge J; Seagen, Bothell, WA, USA.
  • Campbell M; Seagen, Bothell, WA, USA.
  • McGregor B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Balar AV; Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.
Lancet Oncol ; 22(6): 872-882, 2021 06.
Article en En | MEDLINE | ID: mdl-33991512
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma / Moléculas de Adhesión Celular / Neoplasias Urológicas / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma / Moléculas de Adhesión Celular / Neoplasias Urológicas / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article